REG - Futura Medical PLC - Directors' / PDMR Dealing and Grant of Options

Futura MedicalAnnouncement

06/04/2023 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230406:nRSF6508Va&default-theme=true

RNS Number : 6508V  Futura Medical PLC  06 April 2023

 

6 April 2023

 Futura Medical plc

("Futura" or the "Company")

Directors' / PDMR Dealing and Grant of Options

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys® drug delivery technology currently focused
on sexual health and pain, today announces that it has today, granted options
over a total of 1,934,000 ordinary shares of 0.2p each in the Company
("Ordinary Shares") to employees and Directors, of which 858,000 options were
granted to Directors and PDMRs as detailed below. The options are part of
annual awards made by Futura in accordance with existing share schemes.

 Director    Number       Exercise  Exercise period             Total number     Total number

of options
price
of options
of Ordinary

granted
held following
Shares held

notification

 J H Barder  330,000      43.60p    1 April 2026 - 31 Mar 2033  2,415,716        1,440,972

 A Hildreth  264,000      43.60p    1 April 2026 - 31 Mar 2033  1,772,340        142,857

 K W James   264,000      43.60p    1 April 2026 - 31 Mar 2033  1,945,227        299,581

Of the total 1,934,000 options, 1,046,000 were granted under the Futura
Medical plc Enterprise Management Incentive Scheme, and 888,000 were granted
under the unapproved scheme.

Vesting is subject to the achievement of a performance-related milestone and
that the Director/PDMR/employee remains employed with the Company as at the
date of exercise.  Further disclosures are contained in the tables below.

 ENDS

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted an initial Phase 3 study using MED3000 in ED,
referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A
second confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED patients and
endpoints at 24 weeks, demonstrating that MED3000 presents an effective
clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for OTC classification.

Eroxon® is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile dysfunction
under the brand Eroxon® with a key claim of "Helps you get an erection within
10 minutes". Eroxon® is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by the Company
and also in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved. www.eroxon.com
(http://www.eroxon.com)

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         James Barder
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.2 pence each

     Identification code

                                                                  GB0033278473
 b)  Nature of the transaction                                    Grant of options over Ordinary Shares

 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            -    330,000

 

 
 d)  Aggregated information                                       N/A single transaction

     -         Aggregated volume

     -         Price
 e)  Date of the transaction                                      6 April 2023
 f)  Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A single transaction

e)

Date of the transaction

6 April 2023

f)

Place of the transaction

Outside a trading venue

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Angela Hildreth
 2   Reason for the notification
 a)  Position/status                                              Finance Director and

Chief Operating Officer
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.2 pence each

     Identification code

                                                                  GB0033278473
 b)  Nature of the transaction                                    Grant of options over Ordinary Shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            -    264,000

 
 d)  Aggregated information                                       N/A single transaction

     -         Aggregated volume

     -         Price
 e)  Date of the transaction                                      6 April 2023
 f)  Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A single transaction

e)

Date of the transaction

6 April 2023

f)

Place of the transaction

Outside a trading venue

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Ken James
 2   Reason for the notification
 a)  Position/status                                              Executive Director

and Head of R&D
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.2 pence each

     Identification code

                                                                  GB0033278473
 b)  Nature of the transaction                                    Grant of options over Ordinary Shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            -    264,000

 
 d)  Aggregated information                                       N/A single transaction

     -         Aggregated volume

     -         Price
 e)  Date of the transaction                                      6 April 2023
 f)  Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A single transaction

e)

Date of the transaction

6 April 2023

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFIISFIRIIV